






























The effects of factors or drugs that increase life span 
(geroprotectors) on spontaneous tumor development 
may provide important clues to the interactions of 
aging and carcinogenesis. A number of substances 
were suggested as life span extension means [1-3].   
Being suggested on the current knowledge on factors 
and mechanisms or theories of aging these 
pharmacological interventions in the aging process 
sometime were followed some unfavorable effects.   
The comparison of the data on the mechanisms of 
action of geroprotectors with its influence on the 
development of spontaneous and experimentally 
induced tumors permits to deepen our understanding of 
interactions between two fundamental biological 
processes - aging and carcinogenesis [1,2,4]. The main 
goal of this review is critical evaluation of  available 
data on effects of antidiabetic drugs  on aging 
development in experimental animals and perspectives 
of practical use of the drugs for cancer prevention and 
enhance of healthy aging in humans. 
 
Calorie restriction (CR) is the only known intervention 
in  mammals  that  has  been  shown  consistently to in- 
 
 




























crease life span, reduce incidence and retard the onset 
of age-related diseases, including cancer and diabetes. 
CR has also been shown to increase the resistance to 
stress and toxicity, and maintain function and vitality in 
laboratory mammals of younger ages [3,5-7]. Studies 
in CR rhesus monkeys have produced physiological 
responses strikingly similar to those observed in 
rodents [3,8,9]. Emerging data from these studies 
suggest that long-term CR will reduce morbidity and 
mortality in primates, and thus may exert beneficial 
“anti-aging” effects in humans [3,8-11]. It is worthy to 
note that alongside with point of view that CR can 
work for human beings, there are authors who believe 
that to early to decide it or CR cannot work for human 
beings [3,12-19]. 
 
The crucial event of the action of CR is the reduction in 
the levels of insulin and insulin-like growth factor-1 
(IGF-1) and also increases insulin sensitivity in rodents 
[5,12] as well as in monkeys [9]. In C. elegans and D. 
melanogaster, the mutation modification of genes 
operating in the signal transduction from insulin 
receptor to transcription factor daf-16 ( age-1, daf-2, 
InR, etc.) are strongly associated with longevity 
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new evidence on the role of insulin homologue genes 
and SIR2 homologues in longevity by interacting with 
the  daf-2/age-1 insulin-like signaling pathway and 
regulating downstream targets [21].     
   
Activity of daf-16 counteracts both aging and tumor 
growth in C. elegans.  These two processes are linked 
in nature, because tumor rates invariably rise as an 
animal ages.  Pinkston-Gosse and Kenyon [22] have 
identified 29 daf-16/FOXO-regulated genes that act in 
the insulin/IGF-1 pathway to influence C. elegans 
tumor growth.  Some of these genes are required for 
the entire effect that daf-2 mutations have on cell death, 
but none appear to be required for the entire effect on 
cell division. Because both increased apoptosis and 
reduced cell proliferation contribute to the tumor-
protective effects of daf-2 mutations [23], together 
there downstream genes are likely to act in a 
cumulative fashion to influence tumor growth, much as 
downstream targets of daf-16 appear to act 
cumulatively to influence lifespan [24]. It was shown 
that almost half of the genes that affect tumor growth 
also affect the lifespan of animals that do not have 
tumors, indicating that the ability of the insulin/IGF-1 
pathway to couple longevity and tumor resistance 
extends downstream of DAF-16 [21].  
 
Daf-2 and InR are structural homologues of tyrosine 
kinase receptor in vertebrata that includes the insulin 
receptor and the IGF-1 receptor. It was shown that in 
vertebrata the insulin receptor regulates energy 
metabolism whereas IGF-1 receptor promotes a 
growth. During last years series of elegant experiments 
in mice and rats in which this or that key elements of 
the insulin/IGF-1 signaling pathway were genetically 
modified provide an evidence of the involvement of the 
system in the control of mammalian aging and 
longevity [25]. Recently it was shown that in mice, less 
insulin receptor substrate-2 (Irs2) signaling throughout 
the body or just in the brain extended life span up to 
18% [26]. Kapeller et al. [27] showed that partial 
inactivation of brain IGF receptors (IGF-1R) in 
embryonic brain selectively inhibited GH and IGF-1 
pathways after birth. This causes growth retardation, 
smaller adult size, and metabolic alterations, and led to 
delayed mortality and longer mean life span. The mean 
life span in bIGF1RKO
+/- mice was increased by 9.3% 
(p<0.05) as compared with control mice, and tumor 
incidence was 44% and 53%, correspondingly 
(p>0.05). 
 
Selman et al. [28] measured the life span of mice 
lacking either insulin receptor substrate (IRS) 1 or 2, 
the major intracellular effectors of the insulin/IGF-1 
signaling (IIS) receptors. It was observed that female 
Irs1
-/- mice are long-lived. Furthermore, they displayed 
resistance to a range of age-sensitive markers of aging 
including skin, bone, immune, and motor disfunction. 
These improvement in health were seen despite mild, 
lifelong insulin resistance. Thus, enhanced insulin 
sensitivity is not a prerequisite for IIS. Irs1
-/-  female 
mice also displayed normal anterior pituitary function, 
distinguishing them from long-living somatotrophic 
axis mutants. In contrast, Irs2
-/- mice were short-lived, 
whereas Irs1
+/- and Irs2
+/- mice of both sexes showed 
normal life spans. 
 
It was shown that the incidence of mutations in insulin 
regulatory region (IRE) of APO C-III T-455 C directly 
correlates with longevity in humans. This is the first 
evidence showing that mutation located downstream to 
daf-16 in insulin signal transduction system is 
associated with longevity [29]. It is worth noting that 
centenarians display lower degree of resistance to 
insulin and lower degree of oxidative stress as 
compared with elderly persons before 90 years [30,31]. 
The authors suggest that centenarians may have been 
selected for appropriate insulin regulation as well as for 
the appropriate regulation of tyrosine hydroxylase (TH) 
gene, whose product the rate is limiting in the synthesis 
of catecholamines, stress-response mediators. It was 
shown that catecholamine may increase free radical 
production through induction of the metabolic rate and 
auto oxidation in   diabetic animals [32]. A study on 
aging parameters of young (up to 39) and old (over 70) 
individuals having similar IGF-1 serum levels provides 
evidence of important role of this peptide for life 
potential [33]. Roth et al. [34] analyzed data from the 
Baltimore Longitudinal Study of Aging and reported 
that survival was greater in men who maintained lower 
insulin level.  In women, genetic variation causing 
reduced insulin/IGF-1 signaling pathway activation is 
beneficial for old age survival [35]. 
 
Hyperglycemia is an important aging factor involved in 
generation of advanced glycosylation end products 
(AGEs) [36-38]. Untreated diabetics with elevated 
glucose levels suffer many manifestations of 
accelerated aging, such as impaired wound healing, 
cataracts, vascular and microvascular damage [39]. The 
accumulation of the AGE, pentosidine, is accelerated in 
diabetics and has been suggested to be a reliable 
biomarker of aging [36]. The action of insulin provides 
the major modulator of glucose storage and utilization. 
It is important to stress that hyperinsulinemia is also an 
important factor in development of cancer [39,40-45]. 
The concept of CR mimetics is now being intensively 
explored [11,46-51]. CR mimetics involves inter-
ventions that produce physiological and anti-aging 
   
www.impactaging.com                  761                                   AGING,    November 2010, Vol.2 No.11effects similar to CR. Reviewing the available data on 
the benefits and adverse effects of CR and genetic 
modifications, Longo and Finch [52] suggested three 
categories of drugs which may have potential to 
prevent or postpone age-related diseases and extend life 
span: drugs that (i) stimulate dwarf mutations and 
therefore decrease pituitary production of growth 
hormone (GH); (ii) prevent IGF-1 release from the 
liver, or (iii) decrease IGF-1 signaling by the action on 
either extracellular or intracellular targets.  
 
The antidiabetic drugs, phenformin (1-
phenylethylbiguanide), buformin (1-butylbiguanide 
hydrochloride) and metformin (N,N-dimethyl-
biguanide) were observed to reduce hyperglycemia, 
improve glucose utilization, reduce free fatty acid 
utilization, gluconeogenesis, serum lipids, insulin, IGF-
1, reduce body weight and decrease metabolic 
immunodepression both in humans and rodents 
[39,40,53,54]. Nowadays, phenformin is not used in 
clinical practice due to it side effects (mainly lactic 
acidosis) observed in patients with non-compensated 
diabetes. It is worthy of note that during more than 10-
year-long experience of administration of phenformin 
to patients without advanced diabetes Vladimir M. 
Dilman and Lev M.Berstein [55-61] observed no cases 
of lactic acidosis or any other side effects. We believe 
that the analysis of results of long-term administration 
of this drug as well as another antidiabetic biguanides 
(buformin and metformin) to non-diabetic animals is 
seems very important for understanding of links 
between insulin and longevity on the one hand and 
between insulin and cancer on the other hand. 
 
 Biguanides and Life Span 
 
Fourty years ago, it was suggested to use biguanides as 
a potential anti-aging treatment [39,62]. There are data 
on effect of the drugs on life span in worms, mice and 
rats. Buformin was supplemented to nutrient medium 
in various concentrations (from 1.0 to 0.00001 mg/ml) 
during the larvae stage and over the life span of C. 
elegans. The drug given at the concentration of 0.1 
mg/ml increased the mean life span of the worms by 
23.4% (p < 0.05) and the maximum life span by 26.1% 
as compared to the controls [63].  Metformin 
supplementation (50 mM dose) was shown to increase 
the mean life span, but not maximum, of C. elegans, 
although 10 or 100 mM doses showed no significant 
life span benefit [64]. The authors have shown that 
metformin prolongs nematode healthspan, slowing 
lipofuscin accumulation, extending mean life span, and 
prolonging youthful locomotor ability in a dose-
dependent manner. Genetic data suggest the metformin 
acts through a mechanism similar to that operative in 
eating-impaired CR mutants, but independent of insulin 
signaling pathway. Energy sensor AMPK and AMPK-
activating kinase LKB1, which are activated in 
mammals by metformin treatment [65,66], are essential 
for health benefits in C. elegans, suggesting that 
metformin engages a metabolic loop conserved across 
phyla [64]. It was also shown metformin activated 
SKN-1/Nrf2, oxidative stress-responsive transcription 
factor.    
  
The available data on effect of antidiabetic biguanides 
on life span in mice and rats are summarized in the 
Table 1. Female C3H/Sn mice were kept from the age 
of 3.5 months at standard ad libitum diet were given 
phenformin 5 times a week orally at a single dose 2 
mg/mouse until a natural death [67]. The treatment 
with phenformin prolonged the mean life span of mice 
by 21% (p < 0.05), the mean life span of last 10% 
survivors by 28% and the maximum life span by 5.5 
months (by 26%) in comparison with the control. At 
the time of death of the last mice in the control group 
42% of phenformin-treated mice were alive. In this 
study food consumption in control and drug-exposed 
groups was not measured.  
 
Phenformin was given 5 times a week to female 
outbred LIO rats starting from the age of 3.5 month 
until a natural death in a single dose of 5 mg/rat/day 
orally [1,73].  Administration of phenformin failed to 
influence the mean life span in rats. At the same time, 
the mean life span of the last 10% survivors was 
increased by 10% (p < 0.005), and maximum life span 
was increased by 3 months (+ 10%) in comparison with 
the controls. The treatment with phenformin slightly 
decreased the body weight of rats in comparison with 
the control (p > 0.05). The disturbances in the estrus 
function observed in 36 % of 15-16-month old rats of 
the control group and only in 7% of rats in phenformin-
treated group (p < 0.05).  
 
Buformin was given 5 times a week to female LIO rats 
starting from the age of 3.5 month until a natural death 
in a single dose of 5 mg/rat/day orally [73,74]. The 
treatment slightly increased mean life span of rats (by 
7%; p > 0.05). The mean life span of the last 10% 
survivors increased by 12%  (p < 0.05) and the 
maximum life span increased by 2 months (+5.5%) as 
compared with controls. The body weight of rats 
treated with buformin was slightly (5.2 to 9.4%) but 
statistically significantly (p < 0.05) decreased in 
comparison with the control from the age of 12 months 
to 20 months (p < 0.05). At the age of 16-18 months 
38% of control rats revealed the disturbances in the 
estrus cycle persistent estrus, repetitive pseudo-
pregnancies or anestrous), whereas in females treated 
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in 9% of rats (p < 0.05).  Again, in both  these studies 
food consumption in control and drug-exposed groups 
was not measured. 
 
Long-term administration of metformin (100 mg/kg in 
drinking water) slightly decreased the food 
consumption but did not changed the body weight or 
temperature, slowed down the age-related rise in blood 
glucose and triglycerides level, as well as the age-
related switch-off of estrous function, prolonged the 
mean life span by 8% (p < 0.05), the mean life span of 
last 10% survivors by 13.1%, and the maximum life 









































comparison with  the control animals [68]. The 
demographic aging rate represented by the estimate of 
respective Gompertz’s parameter was decreased 2.26 
times. The reduction of the serum level of cholesterol 
and beta-lipoproteins was observed in metformin-
treated transgenic HER-2/neu female mice [68]. 
Metformin treatment decreased the food consumption 
in these mice at the age of 4 and 6 months, suggesting 
that “voluntary CR” may be the sourse of the effects of 
metformin [3].  In our new experiment metformin was 
given to male and female 129/Sv mice [72]. It was 
observed slight increase in mean and maximum life 
span in females but reduction of the mean life span by 












































Strain Sex  Treatment  No.  of 
animals 
Life span, days  References  





C3H/Sn Female  Control  30  450 ± 23.4  631 ± 11.4  643 [67] 
Phenformin 24  545 ± 39.2 
(+21.1%) 




FVB/N Female  Control  34  264 ± 3.5  297 ± 7.3    311 [68] 
Metformin 32  285 ± 5.2 
(+8.0%) 




FVB/N Female  Control  15  285 ± 12   396 ± 0  396 [69] 
Metformin 20  304 ± 10  352 ± 7  359 
SHR Female  Control  50 388 ± 29.2  727 ± 22.5  814 [70] 
Metformin 50  535 ± 31.9*   
(+37.9%) 




NMRI Female  Control  50  346 ± 11.9  480 ± 9.2  511 [71] 
Diabenol 50  369 ± 12.9  504 ± 6.4* 
(+5.9%) 
518 
129/Sv  Male  Control  41  662 ± 27.7  951 ± 32.3  1029  [72] 
Metformin  46  573 ± 26.5      
(-13.4%)* 
931 ± 30.4 
 
1044 
129/Sv  Female  Control  47  706 ± 20.8  910 ± 8.9  930 
Metformin  48  742 ± 16.3 
(+5.1%) 
913 ± 19.2  966 
(+3.9%) 
Rat 
LIO Female  Control  41  652 ± 27.3  885 ± 11.3  919 [1,73] 




Female Control  74  687 ± 19.2  925 ± 22.5  1054 [74] 








Male Control  31  796 ± 170  1039 ± 29.6  1065 [75] 
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with metformin (100 mg/kg in drinking water) slightly 
modified the food consumption but decreased the body 
weight after the age of 2 months (p<0.01), increased 
the mean life span of last 10% survivors by 20.8% 
(p<0.01), and maximum life span by 2.8 months 
(+10.3%) in comparison with the control SHR mice 
[700]. The treatment with metformin failed to influence 
blood estradiol concentration and spontaneous tumor 
incidence in female SHR mice.  
 
 Transgenic mice with Hungtington’s disease (HD) (the 
R6/2 line expressing exon 1 of the hungtington protein 
including ~130 glutamine repeats) were given 
metformin in drinking water (2 or 5 mg/ml) starting 
from the age of 5 weeks [76]. Metformin treatment 
significantly prolonged (by 20.1%) the survival time of 
male (but not female) HD mice at the 2 mg/ml dose (~ 
300 mg/kg/day) without affecting fasting blood glucose 
level. This dose of the drug also decreased hind limb 
clasping time in 11-week-old mice. The higher dose of 
metfromin did not prolong life span, and neither dose 
was effective in female HD mice.  
 
In the study of Smith et al. [75], six month old male 
F344 rats were randomized to one of four diet: control, 
calorie restricted (CR), metformin (300 mg/kg/day) and 
pair fed to metformin. The CR group had significantly 
reduced food intake and body weight throughout the 
study. Body weight was significantly reduced in the 
metformin group compared with control during the 
middle of the study, despite similar weekly food intake.  
There were no significant differences in the mean life 
span or the mean of the last surviving 10% of each 
group in the  CR, metformin and pair fed groups 
compared with control. However, the aging rate 
estimate (α – slope, rate of increase of mortality) of the 
Gompertz model of the control group alone was 
significantly different from the three other groups, 
reflecting the early deaths in the CR, metformin and 
pair fed groups. CR significantly increased life span in 
the 25th quantile but not the 50th, 75th, or 90th 
quantile. The groups of rats exposed to metformin or to 
the pair feeding were not significantly different from 
controls at any quantile [75].  The authors stressed the 
one limitation of this study – the lack of a robust CR 
response for extension of maximum life span which has 
been observed in another the CR study using the same 
strain of rats [19]. The reduced efficacy of CR in this 
study might provide a partial explanation for the lack 
of a significant increase with metformin treatment.  In 
addition to the dampened CR response, metformin 
treatment did not significantly affect glucose/insulin 
levels in this study. The metformin concentration 
utilized in the diet is approximately 10 times that of the 
highest dose used in human treatments, implying that 
any increase necessary to observe life span benefits is 
questionable for a human application [75]. 
 
There are only few data on the effect of other than 
biguanides antidiabetic drugs on life span of animals. 
The effects of new antidiabetic drug Diabenol® (9-β-
diethyl-aminoethyl-2,3-dihydro-imidazo-(1, 2-α) benzi-
midazol dihydrochloride) on life span of NMRI and 
transgenic HER-2/neu mice have been studied [71]. 
Diabenol was synthesized in Rostov State University 
and its hypoglycemic activity was evaluated as 1.5 
times more effective than of maninil (glibenclamide) 
and equal to the effect of glyclazide (pioglitazone) in 
rats, rabbits and dogs [77,78]. Diabenol restores 
increases tissue susceptibility to insulin and extends 
hypoglycemic effect of the hormone. It increases 
glucose utilization in glucose loading test in the old 
obese rats. It was suggested that diabenol influence 
insulin receptors in peripheral tissues. Diabenol 
increases uptake of glucose by isolated rat diaphragm 
in vitro both without supplementation of insulin into 
the medium or with supplemented insulin. Diabenol 
also decreases platelet and erythrocyte aggregation and 
blood viscosity, inhibits mutagenic effect of 2-
acetylaminofluorene and has antioxidant activity 
[77,79,80]. It is shown that treatment with the drug 
failed influence body weight gain dynamics, food and 
water consumption and the body temperature, slowed 
down age-related disturbances in estrous function and 
increased life span of all and 10% most long-living 
NMRI mice [71]. Diabenol treatment slowed down 
age-related changes in estrous function in HER-2/neu 
mice, failed influence survival of these mice.   
 
Thus, available data gives evidence that antidiabetic 
drugs in some cases can increase survival of rodents 
(Table 1). This effect was not observed in all 
experiments and varied depending on strain and species 
of animals. Female mice and rats have been treated in 
the majority of these studies. The experiments with 
males of different strains will be useful for conclusion 
on geroprotective potential of antidiabetic biguanides.  
Metformin is now a widely prescribed medication for 
treating type 2 diabetes. In addition to improving the 
metabolic profile of diabetes, increased survival from 
all-cause mortality has been associated with metformin 
treatment in both diabetic and cardiovascular disease 
patients [81,82].  
 
Biguanides and Endocrine System 
 
Parameters of reproductive function are among most 
valuable biomarkers of aging [83]. The treatment with 
phenformin decreased hypothalamic threshold of the 
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which is one of the most important mechanisms 
regulating age-related decline and switch-off of the 
reproductive function [39,62,86,87]. It is worthy of 
note that another antidiabetic biguanide, metformin, 
may improve menstrual regularity, leading to 
spontaneous ovulation, and enhance the induction of 
ovulation with clomiphene citrate in women with 
polycystic ovary syndrome [88,89].  The treatment 
with phenformin also decreased hypothalamic 
threshold sensitivity to feedback regulation by 
glucocorticoids and by metabolic stimuli (glucose and 
insulin) [39]. It was recently shown that elements 
involved in the insulin/IGF-1 signaling pathway are 
regulated at the expression and/or functional level in 
the central nervous system. This regulation may play a 
role in the brain’s insulin resistance [90], in the control 
of ovarian follicular development and ovulation [91], 
and brain’s control of life span [92,93]. Antidiabetic 
biguanides also alleviated age-related metabolic 
immunodepression [39,40]. These mechanisms can be 
involved in geroprotective effect of biguanides.  
 
Treatment with chromium picolinate which elevated 
the insulin sensitivity in several tissues, including 
hypothalamus, significantly increased the mean life 
span and decreased the development of age-related 
pathology in rats [94]. It was hypothesized that 
antidiabetic biguanides and possibly chromium 
picolinate, have regulate tyrosine hydroxylase and 
insulin/IGF-1 signaling pathway genes both 
associated with longevity [10,95,96]. It was shown 
that the polymorphism at TH-INS locus affects non-
insulin dependent type 2 diabetes [97], and is 
associated with hypothalamic obesity [98], polycystic 
ovary syndrome [99], hypertriglyceridemia and 
atherosclerosis [100].  
 
Anti-tumor Effects of Biguanides  
 
Nowadays there are a burst of data on anti-tumor 
effects of biguanides both in vitro and in vivo [for 
review see: 45,69,101,102]. In this paper we shall not 
to discuss this aspect of the biguanides’ potential. 
However the capacity of the biguanides to prevent 
spontaneous and tumorigenesis induced by chemical 
carcinogens or ionizing irradiation  will be briefly 
analyzed.   Long-term treatment with phenformin   
significantly inhibited (by 4.0-fold, p < 0.01) the 
incidence of spontaneous mammary adenocarcinomas 
in female C3H/Sn mice [67]. The tumor yield curve 
rise was also significantly slowed down as a result of 
the treatment. The treatment with phenformin was 
followed by 1.6-fold decrease in total spontaneous 
tumor incidence in rats, whereas total tumor incidence 
was decreased by 49.5% in buformin-treated rats 
[73,74].  
 
The anticarcinogenic effect of antidiabetic biguanides 
has been demonstrated in several models of induced 
carcinogenesis (Table 2).  
 
Daily oral administration of phenformin or buformin 
suppressed 7,12-dimethylbenz(a)anthracene (DMBA)-
induced mammary tumor development in rats 
[73,111,112]. Phenformin-treated rats revealed a 
tendency toward a decrease in serum insulin level. The 
treatment with phenformin normalised the tolerance to 
glucose and serum insulin and IGF-1 level in rats 
exposed to intravenous injections of N-nitro-
somethylurea (NMU) and inhibited mammary 
carcinogenesis in these animals [113]. Treatment of 
rats with 1,2-dimethylhydrazine (DMH) (once a week 
during 4 weeks) caused the decrease in the level of 
biogenic amines, particularly, of dopamine in the 
hypothalamus, the decrease of glucose tolerance and 
the increase of the blood level of insulin and 
triglycerides. The exposure to DMH also caused the 
inhibition of lymphocyte blastogenic response to 
phytohemagglutinin and lipopolysaccharide, the 
decrease in the level of antibody produced against 
sheep erythrocytes and the decrease in phagocytic 
activity of macrophages [117]. Administration of 
phenformin started from the 1st injection of the 
carcinogen restored all the above mentioned 
immunological indices and inhibited DMH-induced 
colon carcinogenesis [117,118]. It is worthy to note 
that colon 38 adenocarcinoma growth was significantly 
inhibited in liver-specific IGF-1-deficient mice 
whereas injections with recombinant human IGF-1 
displayed sufficiently promoted the tumour growth and 
metastasing [122]. 
 
A decrease of glucose utilisation in the oral glucose 
tolerance test was found in the 3-month-old female 
progeny of rats exposed to NMU on the 21st day of 
pregnancy [115]. The serum insulin level was not differ 
from the control, but the cholesterol level was higher in 
offspring of NMU-treated rats as compared with the 
control. Postnatal treatment with buformin started from 
the age of 2 months significantly inhibited the 
development of malignant neurogenic tumors in rats 
transplancentally exposed to NMU. Similar results 
have been observed in rats exposed transplacentally to 
N-nitrosoethylurea (NEU) and postnatally to 
phenformin [116]. Authors observed the decrease of 
development of nervous system and renal tumors 
induced transplacentally with NEU. The treatment with 
phenformin inhibited also the carcinogenesis induced 
by a single total-body X-rays irradiation in rats [119].  
   











































Vinnitski and Iakumenko [103] have shown that 
treatment with phenformin increased the 
immunological reactivity and inhibited carcinogenesis 
induced by s.c. administration of 20-methyl-
cholanthrene in BALB/c mice.  
 
It was shown that metformin suppresses both 
azoxymethane-induced colorectcal aberrant crypt foci 
[106] and lung carcinogenesis induced by tobacco 
carcinogen in mice [110]. It inhibits also 
benzo(a)pyrene-induced skin and cervico-vaginal 












































In high fat-fed hamsters, the treatment with N-
nitrosobis-(2-oxopropyl) amine was followed by the 
development of pancreatic malignancies in 50% of 
cases, whereas no tumors were found in the hamsters 
treated with the carcinogen and metformin [121].  
  
The effects of new antidiabetic drug Diabenol®  on 
spontaneous tumor incidence in NMRI and transgenic 
HER-2/neu mice as well as on colon carcinogenesis 
induced by 1,2-dimethylhydrazine in rats are studied 
[71]. The treatment with diabenol inhibited spon-
taneous tumor incidence and increased the mammary 
Table 2. Effect of antidiabetic drugs on carcinogenesis in rodents 
 
Drug Carcinogen  Main  target(s)  Effect  References 
Mouse 
Phenformin Spontaneous  Mammary  gland  Inhibition  [67] 
Phenformin  20-methylcholantrene  Subcutaneos soft tissues  Inhibition  [103] 
Diabenol HER2/neu  Mammary  gland  Inhibition  [71] 
Metformin HER2/neu  Mammary  gland  Inhibition  [68,69] 
Metformin  Spontaneous  Mammary gland  No effects  [70] 
Diabenol Spontaneous  Mammary  gland  Inhibition  [71] 
Metformin Spontaneous,  Apc
Min/+ Small  intestines  Inhibition  [104] 
Metformin Spontaneous,  PTEN+/-  Lymphoma, intestine  Inhibition  [105] 
Phenformin Spontaneous,  PTEN+/-  Inhibition 
Metformin  Azoxymethane  Colon   Inhibition   [106] 
Metformin Estradiol,  tamoxifen  Endometrium  Inhibition  [107] 
Metformin  Benzo(a)pyrene   Cervix utery and vagina  Inhibition  [108] 
Metformin Benzo(a)pyrene  Skin  Inhibition  [109] 
Metformin NNK  Lung  Inhibition  [110] 
Rat 
Buformin   Spontaneous  Total incidence  Inhibition  [73,74] 
Phenformin Spontaneous  Total  incidence  Inhibition  [73] 
Phenformin DMBA  Mammary  gland  Inhibition  [111,112] 
Phenformin N-nitrosomethylurea  Mammary  gland    Inhibition  [113] 
Buformin DMBA  Mammary  gland  Inhibition [114] 
Buformin N-nitrosomethylurea, 
transplacentally 
Nervous system  Inhibition  [115] 
Phenformin N-nitrosoethylurea, 
transplacentally 
Nervous system, kidney  Inhibition  [116] 
Phenformin 1,2-dimethylhydrazine Colon  Inhibition [117,118] 
Diabenol 1,2-dimethylhydrazine Colon  Inhibition  [71] 
Phenformin X-rays  Total  incidence  Inhibition  [119] 
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down age-related changes in estrous function in HER-
2/neu mice, failed influence survival of these mice and 
slightly inhibited the incidence and decreased the size 
of mammary adenocarcinoma metastases into the lung. 
In rats exposed to DMH, treatment with diabenol 
significantly inhibited multiplicity of all colon tumors, 
decreased by 2.2 times the incidence of carcinomas in 
ascending colon and by 3.1 times their multiplicity. 
Treatment with diabenol was followed by higher 
incidence of exophytic and well-differentiated colon 
tumors as compared with the control rats exposed to 
the carcinogen alone (76.3% and 50%, and 47.4% and 
14.7%, respectively). Thus, antidiabetic drugs inhibits 
spontaneous and induced carcinogenesis in rodents. 
 
Antidiabetic Drugs and Cancer Risk in Human 
 
There are evidences that insulin resistance or some 
other aspect of type 2 diabetes may promote breast and 
some other cancers [39,123,124]. Biguanides were 
used as a component of the so-called metabolic 
rehabilitation of breast and colon cancer patients 
[39,55,56]. The total of 324 patients (182 with breast 
cancer and 142 with colon cancer) treated by surgery of 
the primary tumor were andomly divided into control 
and treatment groups. In the latter group, diet with 
reduction of saturated fats and cholesterol was 
complemented by biguanides or hypolypidemic drugs 
(mainly clofibrate in breast cancer patients).  Among 
patients treated with biguanides 304 were given the 
drug more than 3 years and 15% more than 5 years. 
The authors reported an overall improvement in the 
cumulative survival by 3-6 and 4-7 years of 
observation in groups with breast and colon cancer, 
respectively, as well as a slight decrease in frequency 
of primary multiple neoplasms and metachronous 
tumors in the contralateral breast [39,55-61]. Evans et 
al. [125] reported results of a pilot case-control study 
on 11 876  diabetic patients treated or not treated with 
metformin. Authors collated information about use of 
metformin for all cases and controls and calculated 
unadjusted odds ratios of cancer risk using conditional 
logistic regression.  More than a third (336; 36.4%) of 
the cases had been given at least on prescription of 
metformin in the year before their index date compared 
with 732 (39.7%) of the controls. The unadjusted odds 
ratio of cancer risk was estimated as 0.86 (95% 
confidential interval - 0.73 to 1.02). The unadjusted 
odds ratio for any exposure to the drug since 1993 was 
0.79 (0.67 to 0.93). It is worthy to note that the authors 
suggested a dose-response relationship: adjusted odds 
ratio for patients dispensed total amount 14 - 672 g of 
metformin was 0.83 (0.65 to 1.06), dispensed 673 – 
964 g of metformin – 0.86 (0.68 to 1.10) and dispensed 
more than 964 g - 0.57 (0.43 to 0.75).  
 
In another study, cancer-related mortality was 
compared among inception cohorts of metformin users 
and sulfonylurea monotherapy users [126].  There were 
10,309 new users of metformin or sulfonylurea with an 
average follow-up of 5.4 ± 1.9 years. Cancer mortality 
over follow-up was 4.9% (162 of 3,340) for 
sulfonylurea monotherapy users, and 3.5 (245 of 6,969) 
for metformin users (p = 0.01 for χ2 test) and 5.8 (84 of 
1,443) for patients who used insulin. Multivariate 
adjustment has shown that the sulfonylurea cohort had 
greater cancer-related mortality compared with the 
metformin cohort (1.3 (95% CI 1.1-1.6); p = 0.012), 
whereas insulin use was associated with an adjusted 
cancer-related mortality of 1.9 (1.5 – 2.4; p < 0.0001). 
In a prospective study, it was found (after a median 
follow-up time of 9.6 years) that metformin use at 
baseline was associated with less cancer-related 
mortality [127]. 1 353 patients with type 2 diabetes 
were enrolled in the project. Of the patients, 570 died, 
of which 122 died of malignancies. The standardized 
mortality rations (SMRs) for cancer mortality was 1.46 
(95% CI 1.22 – 1.76). In patients taking metformin 
compared with patients not taking metformin at 
baseline, the adjusted hazard ration for cancer mortality 
was 0.43 (95% CI 0.23 – 0.80). Cochrane report 
stressed that there were either insufficient or no data on 
the relative efficacy of metformin for preventing the 
development of diabetes, cardiovascular disease, or 
endometrial cancer [128].  
 
Mechanisms of Effects of Biguanides on Aging and 
Cancer 
 
It is worthy to note that studies of metfromin 
distribution in mice showed that 2 hour after a single 
oral dose of 14C metfromin (150 mg/kg) there was a 
measurable accumulation of the drug in brain tissue 
[129]. It was shown that orally administered metformin 
increases brain AMPK activation [76]. This suggests 
that metfromin crossed the blood-brain barrier and 
exert a pharmacological effect in intact brain. 
 
Data on molecular mechanisms of inhibitory effect of 
biguanides on tumor growth have been discussed in 
several recent papers [49-51,101,102,130-137]. The 
formation and accumulation of advanced glycation end 
products (AGE) in various tissues are known to be 
involved in aging process and complications of long-
term diabetes [36,37]. Effects of biguanides buformin 
and metformin on AGE formation have been studied in 
vitro [138]. It  was shown  that both drugs  are potent  
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trial, 6-month-long metformin treatment of women 
with polycystic ovary syndrome (PCOS) significantly 
reduced AGE levels [139]. The AGE formation 
contributes in the increase atherogenic oxidative 
modification of low-density lipoproteins (LDL). The 
impact of glycemic control on the parameters of free 
radical oxidation has been studied in type 2 diabetic 
patients treated with metformin or sulfonylurea 
preparations [140]. Metformin was more effective in a 
decrease of glycated hemoglobin (Hb A1c), lipid 
peroxidation, malonic dialdehyde levels in the serum, 
and in increase of SOD and glutathione peroxidase in 
erythrocytes than sulfonylurea drugs. There are 
evidence that metformin primary inhibited complex I 
of the mitochondrial respiratory chain [141-143]. In 
mice, metformin treatment protected against 
adriamycin-induced increase in the serum level of 
malonic dialdehyde and decrease in the serum level of 
glutathione [144].  
 
A number of reports concerning the cellular response to 
and molecular function of metformin have been 
published. Metformin has been shown to activate 
AMP-activated protein kinase [65] and inhibit the 
tyrosine phosphates activity [145]. Metformin has been 
reported to influence hepatic gene expression in 
cultured hepatocytes, with noted alteration in the 
expression of  glucose-6-phosphatase (G6pc), gluco-
kinase, and 3-hydroxy-3-methylglutaryl-Coenzyme A 
synthase 2 (Hmgcs2). These genes, which are related to 
glycolysis-gliconeogenesis or cholesterol metabolisms, 
were assumed to be critical for the action of metformin 
[146]. Global gene expression analysis has been 
performed in liver of obese diabetic db/db mice 3 hours 
after a single administration of metformin (400 mg/kg) 
[147]. It was identified 14 genes that showed at least a 
1.5-fold difference in expression following metformin 
treatment, including a reduction of glucose-6-
phospatase expression. It was recently observed that 
the antidiabetic biguanides metformin ans phenformin 
inhibit mTORC1 signaling, not only in the absence of 
TSC1/2 but also in the absence of AMPK, instead 
depended on the Rag GTPases [148].  
 
Spindler [149] has found that 8 weeks of metformin 
treatment was superior to 8 weeks of caloric restriction 
at reproducing the specific changes in transcript levels 
produced by long-term caloric restriction in the liver of 
mice. The gene expression changes common to 
metformin and CR were associated with xenobiotic 
metabolism, cellular stress, energy metabolism, 
biosynthesis, signal transduction, and the cytoskeleton 
[150]. It was suggested that antidiabetic biguanides 
inhibit metabolic immunodepression, developed in 
animals exposed to carcinogenic agents which is 
similar to the immunodepression inherent to normal 
aging and specific age-related pathology [39,40]. If 
immunodepression is one of the important factors in 
carcinogenesis, then the elimination of metabolic 
immunodepression, which arises in the course of 
normal aging or under the influence of chemical 
carcinogens or ionizing radiation, can provide an 
anticarcinogenic prophylactic effect [1,39,40,117]. 
 
Although it is known that free radicals are produced 
during metabolic reactions, it is largely unknown which 
factor(s), of physiological or pathophysiological 
significance, modulate their production in vivo. It has 
been suggested that hyperinsulinemia may have 
increase free radicals and therefore promote aging, 
independent of glycemia [39,77,78,151,152]. Plasma 
levels of lipid hydroperoxides are higher, and 
antioxidant factors are lower in individuals who are 
resistant to insulin-stimulated glucose disposal but 
otherwise glucose tolerant, nonobese, and 
normotensive [77]. This finding indicates that 
enhanced oxidative stress is present before diabetes 
ensues and therefore cannot simply be explained by 
overt hyperglycemia. There is substantial evidence 
supporting the hypothesis that selective resistance to 
insulin-stimulated (muscle) glucose disposal and the 
consequential compensatory hyperinsulinemia trigger a 
variety of metabolic effects, likely resulting in 
accelerated oxidative stress and aging [39,77].  
 
The antidiabetic biguanides inhibit fatty acid oxidation, 
gluconeogenesis in the liver, increase the availability of 
insulin receptors, decrease monoamine oxidase activity 
[53,54], increase sensitivity of hypothalamo-pituitary 
complex to negative feedback inhibition, and reduce 
excretion of glucocorticoid metabolites and 
dehydroepiandrosterone-sulfate [39]. These drugs have 
been proposed for the prevention of the age-related 
increase of cancer and atherosclerosis, and for 
retardation of the aging process [39,62]. It has been 
shown that administration of antidiabetic biguanides to 
patients with hyperlipidemia lowers the level of blood 
cholesterol, triglycerides, and b-lipoproteins. 
Biguanides also inhibits the development of 
atherosclerosis, reduces hyperinsulinemia in men with 
coronary artery disease. Its increases hypothalamo-
pituitary sensitivity to inhibition by dexa-methasone 
and estrogens, causes restoration of estrous cycle in 
persistent-estrous old rats, improves cellular immunity 
in atherosclerotic and cancer patients, lowers blood 
IGF-1 levels in cancer and atherosclerotic patients with 
type IIb hyperlipoproteinemia. Recently it was shown 
that metformin decreases platelet superoxide anion 
production in diabetic patients [153]. There are 
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Metformin increased glutathione (GSH) levels and 
diminished lipid peroxidation of T cells in mice thus 
the decrease of oxidative stress inhibited proliferation 
of T cells [154].  
 
Morales et al. [155] showed that metformin ameliorate 
gentamicin-induced kidney injury through a 
mitochondria-dependent pathway, normalizing oxidative 
stress and restoring mitochondrial functional integrity 
[156]. It was shown that a single oral administration of 
metfromin (100, 500 or 2500 mg/kg) or multiple (4 or 8 
weeks) treatment (100 or 500 mg/kg) was not toxic or 
cytotoxic in streptozotocin-induced diabetic or control 
non-diabetic rats. Moreover, metfromin protected rat 
bone marrow and sperm cells against the diabetes-
induced genomic instability and decline in the cell 
proliferation [157]. Pretreatment with metformin 
reduced the doxorubicin-induced high frequency of 
micronuclei and protected against the doxorubicin-
induced alteration of MDA and GSH in mice [144]. 
 
The available data on gender-specificity of the life span 
extension effect of metformin will require further 
studies. It is worthy to note that metformin is used 
clinically to treat hyperandrogenemia in females with 
polycystic ovary syndrome. Insulin resistance in these 
patients contributes to the increased levels of free 
androgen, and metformin, as an insulin sensitizing 
agent, is an effective treatment [158]. 
 
It was shown in mice deletion  of ribosomal S6 protein 
kinase 1 (S6K1), a component of the nutrient-
responsive mTOR (mammalian target of rapamycin) 
signaling pathway, led to increased life span and 
resistance to age-related pathologies, such as bone, 
immune, and motor dysfunction and loss of insulin 
sensitivity [28]. Deletion of S6K1 induced gene 
expression patterns similar to those seen in CR or with 
pharmacological activation of adenosine mono-
phosphate (AMP)-activated protein kinase (AMPK), a 
conserved regulator of the metabolic response to CR 
[28]. It is worthy to note, the mean life span extension 
was observed in female (+20.4%) but it was not 
increased in male S6K1
-/- mice. The mean life span of 
oldest 10% survivors and maximum life span were also 
increased only in females. There was no difference in 
the incidence of macroscopic tumors in S6K1
-/-  a n d 
wild type mice. The strain differences in susceptibility 
to metformin could also be a reason of variability in 
response to treatment. It was shown that mean strain-
specific lifespan varied 2- to 3-fold under ad libitum 
feeding and 6- to 10-fold under dietary restriction in 
virgin males and females in 41 recombinant inbred 
strains of mice [159].  Notably, dietary restriction 
shortened life span in more strains than those in which it 
lengthened life. Food intake and female fertility varied 
markedly among strains under ad libitum feeding, but 
neither predicted dietary restricted mice survival. 
Therefore, strains in which dietary restriction shortened 
life spans did not have low food intake or poor 
reproductive potential. These results demonstrate that 




The striking similarities have been described between 
insulin/IGF-1 signaling pathways in yeast, worms, 
flies, and mice [10]. Many characteristics of mice that 
are long lived due to genetic modifications resemble 
effects of caloric restriction in wild-type (normal) 
animals. Comparison of characteristics of exposed to 
these endogenous and exogenous influences shows a 
number of similarities but also some differences. 
Effects of antidiabetic biguanides seems to be more 
adequate in the prevention of age-related deteriorations 
in glucose metabolism and in insulin signaling pathway 
as well as in such important for longevity parameters as 
fertility and a resistance to oxidative stress and 
tumorigenesis than those induced by caloric restriction 
and genetic manipulations. It was recently 
demonstrated by Ligibel et al. [160] that a physical 
activity program significantly lowers insulin levels 
raises the intriguing possibility that lifestyle 
intervention may act as a targeted therapy in breast 
cancer. Metformin use in diabetic patients has been 
associated with reduced cancer incidence and mortality 
in the number of population-based studies. 
Furthermore, there is evidence that metformin may 
have insulin independent direct effects of cancer cells, 
acting as a mammalian target of rapamycin (mTOR 
inhibitor) [101,102,131-137,161-163]. It was suggested 
that this dual action of metformin (insulin reduction 
and mTOR inhibition) makes it a particularly attractive 
target for evaluation in breast cancer 
[50,51,101,102,161,164] as well as some other, e.g. 
colon cancer. It remains to be shown that either 
antidiabetic biguanides  can extend life span 
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